RxDoctor Payments DataLook up a doctor →

Richard Cristea, MD

Neurology · Merrillville, INNPI 1992858641

Payments from drug & device makers

$30,007in general payments, 2019–2025

Across 1,463 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$3K
  • AbbVie$2K
  • Novartis$2K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Amgen$1K
  • plus $17K from 54 others

What the payments were for

  • Consulting fees$3001%
  • Speaking & faculty fees$1310%
  • Food & beverage$29,40098%
  • Education$1771%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen124$3,326
AbbVie(2 entities)159$2,059
Novartis157$1,972
Teva Pharmaceuticals USA, Inc.97$1,802
Jazz Pharmaceuticals Inc.66$1,506
Amgen(2 entities)55$1,463
EMD Serono, Inc.61$1,194
Neurocrine Biosciences, Inc.37$1,178
AstraZeneca27$926
Sanofi34$757
Lilly USA, LLC27$671
Lundbeck LLC34$645
Argenx US, Inc.23$642
Johnson & Johnson(2 entities)28$638
Avadel CNS Pharmaceuticals, LLC20$632
Bristol Myers Squibb23$575
SK Life Science, Inc.26$535
Otsuka America Pharmaceutical, Inc.15$523
Acorda Therapeutics, Inc31$507
Livanova USA, Inc.11$500
TG Therapeutics, Inc.17$472
Axsome Therapeutics, Inc.20$447
Eisai Inc.15$440
Catalyst Pharmaceuticals, Inc.18$433
Takeda Pharmaceuticals U.S.A., Inc.28$418
UCB, Inc.19$397
Pfizer33$364
Acadia Pharmaceuticals Inc23$309
Merz Pharmaceuticals, LLC14$302
MDD US Operations, LLC18$285
Supernus Pharmaceuticals, Inc.11$271
Genentech USA, Inc.14$258
Harmony Biosciences LLC13$242
Neurelis, Inc.7$236
Corium, LLC11$217
CSL Behring7$199
ANI Pharmaceuticals, Inc.7$197
Sunovion Pharmaceuticals Inc.11$184
Adamas Pharmaceuticals, Inc.10$161
Vanda Pharmaceuticals Inc.8$152
Kyowa Kirin, Inc.5$146
Banner Life Sciences, LLC7$120
Biohaven Pharmaceutical Holding Company Ltd.10$119
Inspire Medical Systems, Inc.1$118
Itamar Medical Inc2$110
E.r. Squibb & Sons, L.L.C.5$102
Scilex Pharmaceuticals Inc.6$100
Octapharma USA, Inc.4$87
Mallinckrodt Hospital Products Inc.4$77
Akcea Therapeutics, Inc.4$77
Ironshore Pharmaceuticals Inc.4$70
Alfasigma USA, Inc.5$65
Amneal Pharmaceuticals LLC4$55
Cycle Pharmaceuticals Inc3$52
Otsuka Pharmaceutical Development & Commercialization, Inc.2$51
Abbott2$50
Tanabe Pharma America, Inc.3$49
Avion Pharmaceuticals2$43
Bausch Health US, LLC3$43
Arbor Pharmaceuticals, Inc.1$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,007 in reported general payments places this provider in the 80th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$349,245
Medicare patients
898
Services billed
5,043

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MayzentSiponimod28$276,159
Kesimpta PenOfatumumab27$252,467
Nurtec OdtRimegepant Sulfate51$74,999
BriviactBrivaracetam13$26,179
RexultiBrexpiprazole15$20,186
TrintellixVortioxetine Hydrobromide21$17,352
Rivastigmine87$17,290
Dalfampridine ErDalfampridine33$15,886
UbrelvyUbrogepant11$14,836
RivastigmineRivastigmine Tartrate114$8,441
Emgality PenGalcanezumab-Gnlm11$7,934
Lacosamide26$5,874
Pregabalin70$5,116
AmantadineAmantadine Hcl78$4,621
Gabapentin240$4,619

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$1,972$276,15928 claims
PfizerNurtec Odt$364$74,99951 claims
UCB, Inc.Briviact$397$26,17913 claims
Otsuka America Pharmaceutical, Inc.Rexulti$523$20,18615 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$418$17,35221 claims
AbbVieUbrelvy$2,059$14,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 308 neurology providers in Indiana.

Other neurology in Merrillville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →